OBJECTIVE: Hypoadiponectinemia observed in obesity is associated with insulin resistance, diabetes and atherosclerosis. The aim of the present study was to investigate secretion of adiponectin and its multimeric isoforms by explants derived from subcutaneous adipose tissue (SAT) and visceral adipose tissue (VAT) in obese and non-obese subjects. DESIGN: Paired samples of SAT and VAT and blood samples were obtained from 23 subjects (10 non-obese and 13 obese) undergoing elective abdominal surgery. Total adiponectin quantities and adiponectin isoforms were measured in conditioned media of explants derived from SAT and VAT using enzyme-linked immunosorbent assay and non-denaturing western blot, respectively. RESULTS: Total adiponectin plasma levels were lower in obese than in non-obese subjects (Po0.05). Secretion of total adiponectin in adipose tissue (AT) explants was lower in obese than in non-obese subjects in SAT (Po0.05) but not in VAT. In both, SAT and VAT, the most abundant isoform released into conditioned media was the high-molecular weight (HMW) form. Its relative proportion in relation to total adiponectin was higher in conditioned media of explants from both fat depots when compared with plasma (Po0.001). The proportion of secreted HMW vs total adiponectin was higher in VAT than in SAT explants in the group of non-obese individuals (49.3 ± 3.1% in VAT vs 40.6 ± 2.8% in SAT; Po0.01), whereas no difference between the two depots was found in obese subjects (46.2 ± 3.0 % in VAT vs 46.0 ± 2.4 % in SAT). CONCLUSION: Obesity is associated with the decrease of total adiponectin secretion in SAT. The profile of adiponectin isoforms secreted by SAT and VAT explants differs from that in plasma. Secretion of total adiponectin and HMW isoform of adiponectin are different in obese and non-obese subjects in relation to AT depot.
INTRODUCTION
The excess of body fat may lead to the development of insulin resistance and other features of the metabolic syndrome. It has previously been reported that the excess of visceral fat located in the abdominal cavity is associated with obesity-related disorders and, ultimately, with cardiovascular risk, more closely than excess of subcutaneous fat. 1 --4 The deleterious effects of an accumulation of visceral fat are attributed to its anatomical position with direct portal drainage to the liver and, also, to different molecular and functional characteristics of visceral adipose tissue (VAT) when compared with subcutaneous adipose tissue (SAT). 5 Obesity and metabolic syndrome have been shown to be associated with lower plasma levels of adiponectin, 6 --8 an adipokine predominantly secreted by adipocytes. The production of metabolically active cytokines produced by adipose tissue (AT)---adipocytokines, in obesity is affected in a depot-related manner. 2, 9 Indeed, differences in protein production or gene expression of a number of adipocytokines, including adiponectin, were demonstrated between SAT and VAT. 3,10 --13 Adiponectin is a protein abundantly secreted by AT and is present intracellularly and in the plasma in different multimeric isoforms. 14, 15 Polypeptides of 30 kDa are assembled into different multimers. The basic adiponectin multimer is represented by low-molecular weight (LMW) trimers formed through hydrophobic interactions. The oxidizing environment within the lumen of endoplasmic reticulum favors disulfide bond formation through which trimers can further associate into middle-molecular weight (MMW) hexamers and high-molecular weight (HMW) multimers composed of 12 --18 monomers. 16, 17 Mechanisms that regulate formation and distribution of adiponectin complexes in human AT and the contribution of different AT depots to circulating levels of particular isoforms are not known so far. The major biological effects of adiponectin in liver, muscle and endothelium have been attributed to HMW isoform of adiponectin. 17, 18 Plasma levels of the HMW isoform and the ratio of HMW to total adiponectin are more closely associated with glucose tolerance and insulin sensitivity than total adiponectin. 19, 20 Taking into account the selective decreased levels of circulating HMW adiponectin in individuals with obesity 21, 22 and the different endocrine activity of SAT and VAT, 23 the fat depot-specific alterations of adiponectin isoforms production may be expected.
Up to date, no studies have focused on comparing secretion of adiponectin isoforms in human SAT and VAT. We studied the secretion of adiponectin isoforms in explants derived from paired samples of human VAT and SAT obtained in a group of obese as well as non-obese individuals undergoing elective abdominal surgery. We hypothesized that the adiponectin isoform release differs in subcutaneous and visceral fat depot and, in a depot-specific manner, varies in respect to obesity.
METHODS

Subjects
A total of 23 subjects (15 women and 8 men) (BMI range 22.3 --45.2 kg m À2 ) scheduled to have abdominal surgery were recruited for the study. The entire group was stratified according to BMI into two groups: non-obese (n ¼ 10, BMI p24.9 kg m À2 ) and obese (n ¼ 13, BMI X30 kg m À2 ). Written informed consent to participate in the study was obtained from each subject. All aspects of the study were performed according to the Declaration of Helsinki and approved by the Ethical committee of the Third Faculty of Medicine, Charles University, Prague, Czech Republic.
Protocol
Paired samples of abdominal subcutaneous (SAT) and omental/visceral (VAT) fat were obtained during abdominal surgery (laparoscopic or laparotomic cholecystectomy, hysterectomy or gastric banding) and transferred to laboratory for immediate processing. Anthropometric indices were measured and blood samples were drawn at fasting condition during the patients' admission to the hospital. Blood samples were stored at À80 1C until analysis.
Adipose tissue explants
The samples of AT were washed in saline solution and cut into small pieces. In all, 100 mg of these AT fragments, that is, explants, were incubated in 1 ml Krebs/Ringer phosphate buffer (pH 7.4) supplemented with 40 g l À1 of bovine serum albumin, and 1 g l À1 of glucose at 37 1C in a shaking water bath with air as the gas phase. After 4 h of incubation, the conditioned medium was collected from each sample and immediately frozen and stored at À80 1C until analysis. 24 --26 The experiment was set up in respect to maintain the ratio between AT weight and medium volume for every sample (AT weight normalization). The length of incubation of AT explants with respect to adiponectin secretion was selected according to our previous experiments showing that the kinetic of total adiponectin secretion from AT explants is close to linearity in the interval between 1 h and 6 h of incubation. 26 Given the above mentioned kinetic, concentration at 4 h of AT explants incubation was chosen as representative for analysis of adiponectin isoforms secretion from different AT depots.
Western blot analysis (WB)
WB analysis of adiponectin isoforms was performed as previously described. 26, 27 Briefly, proteins from plasma and conditioned media of explants were separated by native polyacrylamide gel electrophoresis (without b-mercaptoethanol and SDS) and transferred to nitrocellulose membranes. Membranes were incubated with anti-human adiponectin antibody (Rabbit Polyclonal Antibody, Biovendor Laboratory Medicine Inc., Modrice, Czech Republic), and with horseradish peroxidase --coupled goat anti-rabbit IgG (Jackson ImmunoResearch Europe Ltd, Cambridge, UK). Band detection using a chemiluminescent substrate (Luminol, Sigma-Aldrich, Prague, Czech Republic) was developed on a CL-XPosure Film (Thermo Scientific Pierce Protein Research Products, Rockford, IL, USA) and digitized on HP ScanJet 4850. Band intensity and relative proportions of the isoforms were analyzed using Image J software (Java-based image processing program developed at the National Institutes of Health, Bethesda, MD, USA). Signal intensities from the duplicate samples were averaged, normalized to signal for recombinant adiponectin standard and used for statistical analysis.
Distribution of adiponectin isoforms in plasma and secreted by human AT was expressed as a ratio (%) of each isoform to total adiponectin amount (intensity of all isoforms expressed together as 100%).
Plasma analysis and calculations
The conventional laboratory variables were analyzed using commercial kits. The HOMA (homoeostasis model assessment) index was calculated using the following equation: [fasting glucose (mmol l 
Statistical analysis
Statistical analysis was performed using SPSS 12.0. and 17.0 for Windows (SPSS Inc., Chicago, IL, USA). The differences between the groups were tested using the Mann --Whitney test and differences between the SAT and VAT using Wilcoxon Signed Ranks test. Values are presented as means ± s.e.m. Differences at the level of Po0.05 were considered statistically significant.
RESULTS
Clinical characteristics
Anthropometric and biochemical characteristics of subjects are shown in Table 1 . Obese subjects had lower insulin sensitivity expressed as increased HOMA-IR, lower plasma HDL cholesterol and higher plasma triglyceride levels when compared with non-obese individuals.
Plasma levels of total and multimeric forms of adiponectin Plasma levels of total adiponectin were higher in non-obese than in obese subjects (Table 1) . Relative proportions of each of the three isoforms (that is, the proportion of particular isoforms related to total adiponectin) in plasma analyzed by WB, that is, LMW/total adiponectin, MMW/total adiponectin and HMW/total adiponectin, were not different between obese and non-obese subjects (Figure 1 ).
Total adiponectin secretion from AT explants Total adiponectin quantity (mg ml À1 per 100 mg AT) secreted from AT explants into conditioned media was lower in SAT in obese when compared with SAT of non-obese individuals (Figure 2 ). In VAT, there was no significant difference between non-obese and obese subjects. No significant difference in the secretion of total adiponectin was found between SAT and VAT in the entire group, as well as in the group of non-obese or obese individuals.
Adiponectin multimeric isoform secretion from AT explants An example of WB analysis of the adiponectin isoforms secreted by SAT and VAT explants of non-obese and obese subject is shown in Figure 3 . In the entire group, we found no difference in the proportion of secreted isoforms between SAT and VAT. In the group of non-obese subjects, proportion of HMW/total adiponectin secreted by VAT was significantly higher when compared with the secretion by SAT, and proportion of LMW/total adiponectin was lower in VAT than in SAT (Figure 1 ). However, in the obese group no difference in the proportion of HMW and other isoforms (MMW and LMW) between SAT and VAT was observed (Figure 1) . These results were not affected when gender was considered into the analyses.
Assessment of the isoform secretion in absolute terms in respect to fat depot and adiposity may be expressed using the data from semiquantitative WB analysis (absolute values of band quantification). These data are explaining the relative changes of secreted isoforms showing differences in profiles between depots and groups ( Figure 4 ).
Comparison of adiponectin multimeric isoforms: secretion rate vs plasma levels When comparing circulating and secretion profile of adiponectin isoforms, we found a significant difference in their distribution between plasma and conditioned media of VAT and SAT explants (Po0.001) (Figure 1 ). In both, culture media of SAT and VAT explants, the most abundant isoform was the HMW. These data show that HMW is the predominant form secreted from both SAT and VAT, and that, in both AT depots, the profile of adiponectin multimeric isoforms secreted from AT is different from that of plasma. Figure 1 . Profile of secretion of adiponectin isoforms related to secretion of total adiponectin in SAT and VAT explants and plasma isoform profiles in non-obese and obese subjects. individuals. The data show that (1) obesity is associated with lower secretion of total adiponectin in SAT but not in VAT; (2) obesity is associated, in a fat depot-related manner, with alterations in the profile of secreted adiponectin isoforms: namely the relative proportion of HMW is higher in VAT than in SAT in non-obese subjects and not different between the two depots in obese subjects and (3) the profile of adiponectin isoforms secreted by both, SAT and VAT explants, is different from that in plasma.
DISCUSSION
In a number of studies, obesity and related metabolic disorders were shown to be associated with decreased total adiponectin levels in plasma.
6 --8 Accordingly, in our study we found lower plasma adiponectin levels in obese compared with non-obese subjects. Secretion of total adiponectin was impaired in SAT but not in VAT in the obese group. This is in agreement with the study of Murdolo et al., 28 showing lower interstitial adiponectin levels in SAT in obese compared with lean. Regarding adiponectin secretion by fat depots, the literature provides conflicting data. Consistent with our data, the study by Drolet et al. 12 showed no difference in total adiponectin secretion between subcutaneous and omental adipocytes in subjects with a wide range of BMI, with an exception of a subgroup of visceral obese who presented lower omental cell adiponectin release when compared with subcutaneous cells. Motoshima et al. 11 and Perrini et al. 3 reported that the cultured human omental adipocytes secrete more adiponectin than subcutaneous adipocytes and that its secretion is inversely correlated to BMI, whereas the secretion from the subcutaneous cells was unrelated to BMI. Contrary to this, Phillips et al. 29 showed lower adiponectin levels secreted by VAT than SAT explants of obese as well as type 2 diabetic people. These inconsistent findings may be attributed to important methodological differences existing among the studies comparing AT explant cultures and adipocyte cultures. Explant culture preserves both, the structural support of extracellular matrix for adipocytes and the paracrine influence of the many cell types of AT that influence adipocyte function, and may affect adiponectin production.
It is evident that multimerization of adiponectin has an important role for its biological function, and the particular adiponectin isoforms (mainly HMW isoform) appear to be selectively affected by obesity. 30 --32 Depot-specific regulation of the adiponectin isoform secretion might contribute to the selective decline of the metabolically most active HMW isoform in obesity. To date, no human studies investigated distribution of adiponectin isoforms produced by different AT depot in lean and obese subjects. The study of Murdolo et al. 28 examined serum as well as interstitial concentrations of adiponectin in vivo in SAT, and found decreased levels in obese that were due to a decrease in HMW form. In our study, lower concentration of adiponectin in plasma of obese subjects was not accompanied by selective reduction of individual isoforms. However, we observed selective differences between obese and non-obese individuals in respect to the distribution of adiponectin isoforms in secretion media in vitro in SAT-and VAT-derived explants.
The three oligomeric isoforms of adiponectin are present in blood as well as intracellularly and secreted from AT, but the relative proportion of the isoforms varies. 14 We have shown and confirmed here that the profile of adiponectin multimers secreted by AT explants derived from needle biopsies of abdominal SAT differs from their plasma profile 26 and that the main isoform secreted by SAT and VAT explants is the HMW isoform. This is in agreement with other studies, showing HMW as the predominant form secreted by subcutaneous fat. 28, 33 Before reaching the blood circulation, adiponectin must pass through the microenvironment of the interstitial space and cross the endothelial barrier. Due to large molecular size of adiponectin, especially the HMW form, there is limitation in transport across the blood-brain barrier. 34 Similar limitation could be expected at the level of AT endothelial barrier; however, no evidence of a differential transendothelial transport of adiponectin multimers has been revealed. Adiponectin profile might also be influenced beyond AT endothelium level. Although studies on mice suggest that adiponectin injected intravenously does not interconvert once in circulation, 35, 36 more recently Scherer and co-workers 37 showed different clearance rates of plasma adiponectin isoforms in vivo, suggesting HMW as a storage compartment for lower subunits generated upon reduction of the HMW form. HMW isoform may also be, as the major active form, preferentially utilized by liver or other target organs. 16, 37 The study presents limitations that should be acknowledged. Quantification of the adiponectin isoforms was performed using semiquantitative WB method. Percentage expression is therefore preferable for evaluation of the changes of isoform distribution. However, absolute amounts of separate isoforms help in evaluating the contribution of secretion of the isoforms by the two fat depots. Another limitation of this study is that fat cell size was not measured due to the modest amount of fat samples obtained. Adiponectin has been shown to correlate negatively with adipocyte size, 38 --40 although data are inconsistent, and Skurk et al. 41 observed a higher adiponectin production in larger adipocytes. Nevertheless, adipocyte size does not have a role in the assessement of the relative proportion of adiponectin isoforms produced in the two AT depots and the normalization of secretion rate to fat amount provides a more representative image of the contribution of the given fat mass in the two fat depots to the whole-body production of adiponectin. Among factors having a role in the differential isoform secretion in respect to the fat depot, the regulatory interaction between adipokines should be mentioned. For instance, tumor necrosis factor-a showing different expression levels in the two fat depots 42, 43 directly contributes to the reduction of adiponectin in adipocytes, 44 and tumor necrosis factor-a neutralization increases not only total plasma adiponectin levels 45 but also the ratio of HMW to total adiponectin in obese subjects. 46 This suggests other potential mechanisms in the differential regulation of adiponectin isoforms in fat depots.
In summary, obesity is associated with decreased levels of adiponectin in plasma as well as with its secretion from SAT (not VAT). AT location in the body appears to be influential for the isoform secretion. Adiponectin HMW isoform secretion differs in respect to the location of fat depot and in respect to obesity. The results show that obesity affects the secretion of adiponectin isoforms in AT in a fat depot-dependent manner.
